hero-press-releases-1

Newsroom

News

External stories on biodesix

Posts in: blood-based cancer test

CGTV: Biodesix, Bioyong, and Lung Cancer Testing in China—Watch the Video

CGTV (China Television) story on Biodesix's agreement with Bioyong, and why lung cancer tests are needed in China

Putting Lung Cancer in the Bullseye (Breakthroughs)

Lung cancer specialist Karen Reckamp, M.D., is tired of seeing what the disease does to her patients. It all comes down to a blood test called VeriStrat.

Biodesix Feels the Buzz at BIO2012 (FierceBiomarkers)

Biodesix’s business model is based on two strands–clinical diagnostics and companion diagnostics; Tests based on the presence or absence of a biomarker.

A Test to Go With It (GenomeWeb)

Pharmaceutical companies are increasingly turning to companion diagnostic tests to determine whether a drug is suitable for a given patient.

The Burrill Report | Biodesix

Biodesix's Jeffrey Bojar discusses Evolution of Translational Omics: Lessons Learned and the Path Forward and the rigorous framework it provides.

A Better Route for Diagnostics? (Drug Discovery & Development)

The Human Genome Project was expected to yield substantial benefits in diagnostics. But the genome is only part of the story. mRNA are equally as important.

Protein Test Found to Boost NSCLC Survival, Costs (MedPage Today)

Choosing second-line therapy on the basis of a protein-expression test modestly improved survival in patients with advanced non-small cell lung cancer.

Genetic Engineering News | Biodesix

Trial Shows Biodesix Assay Predicts Breast Cancer Response to Femara (Genetic Engineering News)

Serum Profiling Making Mark on Predictive Medicine | Biodesix

Veristrat from Biodesix is an example of a serum-based test used in the clinic that can predict response to a second-line biotherapeutic treatment option.

Getting Personal (Clinical Lab Products)

Molecular diagnostics is heading the way of personalized medicine, aiming to help physicians devise particular treatment plans specific to the patient.

1 2 Last